StocksMedium•2 October 2026•
1 min read
Liquidia Stock Plummets 57% Following Adverse Patent Ruling
Key Facts
1A federal court ruled that Liquidia's YUTREPIA product infringed on patents held by United Therapeutics regarding PH-ILD treatment.
2Liquidia shares plummeted by as much as 57% following the adverse legal ruling.
3Liquidia plans to appeal the decision and remove the PH-ILD indication from YUTREPIA’s label to mitigate the impact.
Liquidia shares plummeted by as much as 57% according to Reuters, following an adverse federal court ruling. The court found that Liquidia's lead product candidate, YUTREPIA, infringed on patents held by United Therapeutics regarding the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Liquidia plans to appeal the decision and remove the PH-ILD indication from YUTREPIA’s label to mitigate the impact, Financial Modeling Prep reported. LQDA closed at $27.99 on October 1, 2026, while rival United Therapeutics (UTHR) closed at $571.38 on the same date.